Puma slips on new neratinib data

Puma Biotechnology Inc. (NYSE:PBY) shed $4.28 to $67.94 on Friday after presenting data showing neratinib (PB272) led to a modest three-year disease-free survival (DFS) benefit as an adjuvant treatment for HER-2 positive early stage breast cancer in the Phase III ExteNET trial.

At three years, 92% of neratinib-treated patients in the trial reached invasive DFS vs. 89.9% of patients in the placebo arm. Both groups had previously undergone surgery and received adjuvant treatment with Herceptin trastuzumab. Puma presented the data at the San Antonio Breast Cancer Symposium. ...